Total for the last 12 months
number of access : ?
number of downloads : ?
ID 117393
Author
Sako, Masahiro Tokushima University|Tokushima Prefectural Central Hospital
Nokihara, Hiroshi Tokushima University
Kondo, Kensuke Tokushima University|Tokushima Prefectural Central Hospital
Yabuki, Yohei Tokushima University
Otsuka, Kenji Tokushima University
Keywords
interstitial pneumonia
pembrolizumab
pulmonary pleomorphic carcinoma
Content Type
Journal Article
Description
Pulmonary pleomorphic carcinoma is often refractory to chemotherapy and follows an aggressive clinical course. Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced lung cancer, and a few cases with pleomorphic carcinoma have been reported to show tumor shrinkage after therapy with ICIs. When treating patients with ICIs, patient selection is essential, and monitoring and management of immune-related adverse events, including pneumonitis, are needed. We herein report a case of pulmonary pleomorphic carcinoma with preexisting interstitial pneumonia treated with pembrolizumab, antiprogrammed cell death 1 antibody. Our report highlights important considerations necessary when treating advanced pleomorphic carcinoma patients complicated with interstitial pneumonia. We also review the literature regarding the use of ICIs in such patients.
Journal Title
Thoracic Cancer
ISSN
17597714
Publisher
China Lung Oncology Group|John Wiley & Sons Australia
Volume
13
Issue
1
Start Page
129
End Page
132
Published Date
2021-12-03
Rights
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
EDB ID
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
University Hospital
Medical Sciences